Literature DB >> 27377903

Response.

Maureen Trudeau1.   

Abstract

Year:  2016        PMID： 27377903      PMCID： PMC5017932          DOI： 10.1093/jnci/djw105

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

1.  Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Authors:  Amadeo M Parissenti; Baoqing Guo; Laura B Pritzker; Kenneth P H Pritzker; Xiaohui Wang; Mu Zhu; Lois E Shepherd; Maureen E Trudeau
Journal:  Breast Cancer Res Treat       Date:  2015-07-25       Impact factor: 4.872

2.  Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.

Authors:  Amadeo M Parissenti; Judy-Anne W Chapman; Harriette J Kahn; Baoqing Guo; Lei Han; Patti O'Brien; Mark P Clemons; Roberta Jong; Rebecca Dent; Barbara Fitzgerald; Kathleen I Pritchard; Lois E Shepherd; Maureen E Trudeau
Journal:  Breast Cancer Res Treat       Date:  2010-01       Impact factor: 4.872

3.  A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Authors:  Maureen Elizabeth Trudeau; Judith-Anne W Chapman; Baoqing Guo; Mark J Clemons; Rebecca A Dent; Roberta A Jong; Harriette J Kahn; Kathleen I Pritchard; Lei Han; Patti O'Brien; Lois E Shepherd; Amadeo M Parissenti
Journal:  Springerplus       Date:  2015-10-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.